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Open access under CC BYThis randomized, open-label, ambulatory, controlled clinical study investigated biomarkers associated
with cardiovascular risk and biomarkers of exposure to 10 selected harmful and potentially harmful con-
stituents (HPHC) in cigarette smoke in 316 male and female Polish smokers. Subjects were randomized to
continue smoking conventional cigarettes (CC; N = 79) or switch to smoking the Electrically Heated Cig-
arette Smoking System series-K cigarette (EHCSS-K6; N = 237). Biomarker assessments were performed
at several time points during the study at baseline and during the 1-month investigational period. The
primary biomarkers were high-sensitivity C-reactive protein and white blood cell counts. No statistically
signiﬁcant differences in the two primary biomarkers were found between the study groups at the end of
the study. End-of-study comparisons of secondary biomarkers between study groups indicated an
increase in high-density lipoprotein cholesterol, and reductions in red blood cell count, hemoglobin,
and hematocrit levels in the EHCSS-K6 group. All biomarkers of exposure to cigarette smoke HPHC were
decreased in the EHCSS-K6 group, despite an increase in cigarette consumption, compared to the CC
group. There were no apparent differences in any of the safety assessment parameters between the
groups, and the overall incidence of study-related adverse events was low.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
There is overwhelming medical and scientiﬁc consensus that
cigarette smoking causes lung cancer, heart disease, emphysema,
and other serious diseases in smokers (US Department of Health
and Human Services, 2010). The Family Smoking Prevention and
Tobacco Control Act (FSPTCA) (Family Smoking Prevention and To-
bacco Control Act, 2009) in the United States has empowered the
Food and Drug Administration (FDA) to evaluate and regulate mod-
iﬁed risk tobacco products (MRTPs) (Deyton et al., 2010). The FDA,
in consultation with the Institute of Medicine (IOM), has also been
charged to issue guidance and regulations on the scientiﬁc evi-
dence required for the assessment and ongoing review of MRTPs
(Food and Drug Administration, 2012; Institute of Medicine, 2012).
’The association between cigarette smoking and cardiovascular
disease (CVD) is well documented. For example, smoking is a cause
of premature atherosclerosis, acute myocardial infarction, sudden
death, and stroke (Burns, 2003; Hatsukami et al., 2006a,b).ette).
-NC-ND license.Signiﬁcant changes in biomarkers related to oxidative stress, endo-
thelial damage, thrombosis, inﬂammation, and lipid metabolism
have been found in smokers (Benowitz, 2003; Hatsukami et al.,
2006a,b; US Department of Health and Human Services, 2010).
Use of the Electrically Heated Cigarette Smoking System
(EHCSS) series-K heater and the EHCSS series-K6 cigarette results
in reduced levels of a wide range of toxicologically important cig-
arette smoke HPHC and signiﬁcantly lowers the biological activity
of mainstream smoke compared to conventional lit-end cigarettes
in laboratory-based test systems (Werley et al., 2008; Zenzen et al.,
2012). By heating tobacco, the temperature reached is lower than
that reached in the burning cone of a conventional lit-end ciga-
rette. Up to 8 puffs can be obtained by smoking an EHCSS series-
K cigarette with the EHCSS heater. Previous clinical investigations
with the EHCSS have found that there are reductions in biomarkers
of exposure to selected cigarette smoke HPHC (Frost-Pineda et al.,
2008a,b; Roethig et al., 2005, 2007). Smokers who switched to an
earlier version of the EHCSS over 12 months also had favorable
changes in several biomarkers associated with CVD (Roethig
et al., 2008). Additionally, the use of an EHCSS results in reductions
of the levels of environmental tobacco smoke (ETS) constituents in
indoor air (Frost-Pineda et al., 2008c; Tricker et al., 2009).
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Fig. 1. Study design and assessment schedule. All subjects were scheduled to
attend the study site on Visit 1 for screening assessments, Visits 2 and 3 for baseline
assessments of biomarkers prior to randomization at Visit 3; and Visits 4 through 8
for study investigations. Study visits were scheduled 7 (±2) days apart.
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EHCSS series-K heater and the EHCSS-K6 cigarette for 1 month
on the levels of biomarkers associated with CVD and selected bio-
markers of exposure to cigarette smoke HPHC in smokers. The bio-
markers associated with CVD included those (white blood cell
count, hematocrit, urine 11-dehydrothromboxane B2, and high-
density lipoprotein cholesterol) for which statistically signiﬁcant
changes were observed in a previous 12-month study evaluating
a second-generation EHCSS (series-JLI) (Roethig et al., 2008). Bio-
markers of exposure were selected for the HPHC 1,3-butadiene,
2-naphthylamine (2-NA), 4-aminobiphenyl (4-ABP), acrolein, ben-
zene, carbon monoxide (CO), 4-(methylnitrosamino)-1-(3-pyri-
dyl)-1-butanone (NNK), nicotine, pyrene, and o-toluidine.
The primary biomarkers investigated were white blood cell
(WBC) count and high-sensitivity C-reactive protein (hs-CRP),
two biomarkers which indicate an inﬂammatory response associ-
ated with CVD and have been shown to be inﬂuenced by smoking
(Abel et al., 2005; Andrews and Tingen, 2006; Bakhru and Erlinger,
2005; Bazzano et al., 2003; Hatsukami et al., 2005).
This is the ﬁnal manuscript in a series of ﬁve clinical evaluations
of the EHCSS describing data from clinical investigations per-
formed under both controlled (Tricker et al., 2012a,b,c,d) and
actual use smoking conditions (this study).2. Materials and methods
2.1. Subjects
Subjects were eligible for enrollment if they were Caucasian
smokers aged 30–60 years with acceptable health conditions. Sub-
jects were current smokers of commercially available, non-men-
tholated conventional cigarettes with a 3–10 mg tar yield with a
smoking history of at least 10 years prior to screening.
Subjects with clinically relevant abnormal ﬁndings based on the
screening assessments were excluded. Pregnant or lactating wo-
men and women of child-bearing potential who were not using
an acceptable method of contraception were also excluded. Sub-
jects were recruited from the clinical site database and were com-
pensated for their participation in the study. All subjects provided
written informed consent and were advised that they were free to
withdraw from the study at any time. Each subject was provided
with advice and information about the risks of smoking, and coun-
seling was made available.2.2. Study design and conduct
This study was approved by the Independent Ethics Committee
of the Regional Chamber of Physicians, Warsaw, Poland, and con-
ducted at MTZ Clinical Research Ltd., Warsaw, Poland (MTZ) in
compliance with the ethical principles that have their origin in
the Declaration of Helsinki (World Medical Association, 1964, as
amended 2004) and International Conference on Harmonisation
Good Clinical Practice (GCP) guidelines (International Conference
on Harmonisation, 1996). The study was conducted in two sessions
between October 2007 and April 2008.
This was a randomized, open-label, controlled study with two
study groups, EHCSS-K6 and conventional cigarettes (CC). The study
schedule consisted of eight main study visits, screening (Visit 1),
two baseline,weekly assessments (Visits 2 and 3), andﬁve post-ran-
domizationweekly assessments (Visits 4–8). Thewhole study dura-
tion was approximately 8 weeks (Fig. 1), with the investigational
period deﬁned as 5 weeks from the date of randomization (Visit 3/
Day 0) to the last study visit (Visit 8/Day 35).
The screening assessment at Visit 1 included the following
assessments: physical examination, vital signs, chest X-ray,electrocardiography (ECG), clinical laboratory, drug screening,
pregnancy test, and collection of demographic data and smoking
history, including the Fagerström Test for Nicotine Dependence
(Heatherton et al., 1991). Blood and urine samples were taken for
serum chemistry, hematology, serology, and urine analysis.
Randomization of subjects was performed at Visit 3 after com-
pletion of the visit-speciﬁc assessments using an Interactive Voice
Response System (IVRS) (Covance, Waterloo, Belgium). Subjects
were randomized to either the EHCSS-K6 group or the CC group,
respectively, stratiﬁed by gender (40–60% of each gender) and
age (50% subjects aged 30–44 years and 50% aged 45–60 years). A
randomization ratio of 3:1 (EHCSS-K6:CC) was used to account
for possible non-compliance in the EHCSS-K6 group.
Subjects randomized to the CC group continued to smoke their
own brand of cigarettes for the duration of the study. Subjects in
the EHCSS-K6 group were asked to exclusively smoke the EHCSS-
K6 cigarette from Visit 3 until the end of the study. Blinding was
not possible due to the differences in physical appearance of the
cigarettes to be used.
The assessment schedule of biomarkers over the course of the
study consisted of blood sampling (in fasted state) on Visits 2, 3,
5, 7, and 8, and a 24-hour urine collection prior to Visits 3 and 8
(for urinary biomarkers). Carbon monoxide breath testing (Smok-
erlyzer, Bedfont Scientiﬁc Ltd., Rochester, UK) was performed at
all visits from Visit 2 through Visit 8.
Adherence to the study protocol and to Good Clinical Practice
was ensured by regular monitoring visits by an independent mon-
itor and by an independent audit of the investigational site.2.3. Cigarette products and compliance
The EHCSS series-K cigarette was analyzed for tar, nicotine and
CO mainstream smoke yields according to International Organiza-
tion for Standardization (ISO) methods. All study cigarettes were
conditioned according to ISO standard 3402 (International Organi-
zation for Standardization, 1991). Mainstream smoke from EHCSS
cigarettes was generated on a modiﬁed smoking machine with a
carousel adapted to use the EHCSS series-K lighter. The EHCSS
smoke generation conformed with ISO standard 3308 (Interna-
tional Organization for Standardization, 2000a); however, some
slight technical deviations were required. Tar, nicotine and CO
were determined according to ISO standards 4387, 10315, and
8454, respectively (International Organization for Standardization,
2000b, 2000c; International Organization for Standardization,
1995). The ISO yields as declared on the EHCSS-K6 pack were as
follows: 5 mg tar, 0.3 mg nicotine, and 1.0 mg CO.
As EHCSS-K6 cigarettes were not commercially available on the
Polish market they were provided free-of-charge to the subjects.
Conventional cigarettes were not analyzed or provided to subjects
in the CC group, and were purchased by the subjects according to
their usual habits.
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EHCSS series-K heater at Visit 3 and up to 30 packs (of 20 cigarettes
each) of the EHCSS-K6 cigarette were provided at Visits 3–7. Un-
used cigarettes EHCSS-K6 cigarettes were returned at the following
visit.
Subjects were trained on the use of the e-diary (PHT LogPad,
PHT Corporation, Charlestown, MA) and were instructed to docu-
ment the number of cigarettes smoked each day from Visits 2
through 8, and to record the use of any other tobacco- or nico-
tine-containing products. These entries were used to assess com-
pliance. In the EHCSS-K6 group, subjects were considered to have
good compliance if they smoked 610% CC and no more than 2 CC
per day, and did not use any other nicotine- or tobacco-containing
products. In the CC group, subjects were considered compliant if
they smoked exclusively conventional cigarettes.2.4. Bioanalytical methods
A detailed sample-handling manual was prepared to describe
the preparation, transport, storage, and analysis of samples. All lab-
oratory analyses were performed in a blinded manner without
knowledge of the study group assignment.
Biomarkers associated with CVD in smokers are listed in Table
1. Hematology analysis was performed on an automated hematol-
ogy analyzer (Sysmex XS-800i; Sysmex Europe GmbH, Norder-
stedt, Germany). hs-CRP was determined by particle-enhanced
immunological agglutination using anti-CRP antibodies coupled
to latex microparticles with a Hitachi 902 chemistry analyser
(Roche Diagnostics GmbH, DE-82377 Penzberg, Germany). An
automated enzyme-linked immunosorbent assay (ELISA) system
(Immunomat™ BASE Plus; Serion Immundiagnostica GmbH, D-
97076 Würzburg, Germany) with commercial ELISA kits was used
to determine interleukin-6 (IL-6) (Ref. No.: 953 030 192 CE; Gen-
Probe Diaclone SAS, 20250 Besancon, France), oxidized low-density
lipoprotein (ox-LDL) (Ref. No.: K7810; Immundiagnostik AG, D-
64625 Bensheim, Germany), myeloperoxidase (MPO) (Ref. No.:
K6631; Immundiagnostik AG, D-64625 Bensheim, Germany), and
von Willibrand factor (vWF) (Ref. No.: 5450201; Technoclone
GmbH, 1230 Vienna, Austria). Fibrinogen was determined by the
Clauss clotting method on a STA Compact Analyzer (Diagnostica
Stago S.A.S., 92602 Asnières sur Seine, France). Urinary 8-epi-pros-
taglandin F2a (8-epi-PGF2a) and 11-dehydro-thromboxane B2 (11-
DTXB2) were determined by liquid chromatography – tandem
mass spectrometry (LC–MS/MS) using an Agilent HP1100 SeriesTable 1
Summary of biomarkers associated with CVD and bioanalytical methods.
Biomarker Matrix M
White blood cell (WBC) count Blood F
WBC differential Blood F
Platelet count Blood D
Red blood cell (RBC) count Blood D
Hemoglobin Blood S
Hematocrit Blood C
High-sensitivity C-reactive protein (hs-CRP) Serum I
Interleukin-6 (IL-6) Serum E
Oxidized low-density lipoprotein (oxLDL cholesterol) Serum E
Myeloperoxidase Serum E
Homocysteine Serum M
High-density lipoprotein (HDL) Serum P
Low-density lipoprotein (LDL) Serum P
Total cholesterol Serum P
von Willebrand factor (vWF) Plasma E
Fibrinogen Plasma C
Adenosine diphosphate (ADP)-induced platelet aggregation Plasma A
8-epi-prostaglandin F2a (8-epi-PGF2a) Urine L
11-dehydro-thromboxane B2 (11-DTXB2) Urine L
ELISA, enzyme-linked immunosorbent assay; Hct, hematocrit; LC–MS/MS, liquid chromaHPLC Value System (Agilent Technologies, D-76337 Waldbronn,
Germany) equipped with an Applied Biosystems/MDS SCIEX 4000
Qtrap triple quadrupole mass spectrometer with Applied Biosys-
tems/MDS Sciex Analyst software version 1.4.2 (Applied Biosys-
tems, Foster City, CA 94404, USA).
Tobacco-speciﬁc and tobacco-related biomarkers of exposure
(Hecht, 2003; Lindner et al., 2011; Schorp et al., 2012) were deter-
mined for the following HPHC (Table 2) using methods validated
according to the FDA criteria (Food and Drug Administration,
2001). These included nicotine and ﬁve metabolites (expressed as
nicotine equivalents: Neq) as a biomarker of exposure for nicotine
(Benowitz et al., 1994), 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanol and its glucuronide conjugates (total NNAL) for NNK
(Carmella et al., 2003), monohydroxybutenyl mercapturic acid
(MHBMA) for 1,3-butadiene (van Sittert et al., 2000), 3-hydroxy-
propyl mercapturic acid (3-HPMA) for acrolein (Mascher et al.,
2001), S-phenyl mercapturic acid (S-PMA) for benzene (Medeiros
et al., 1997), and 1-hydroxypyrene and its sulfate and glucuronide
conjugates (total 1-OHP) for pyrene (Strickland et al., 1996). Uri-
nary concentrations of 2-naphthylamine, 4-aminobiphenyl, and
o-toluidine were measured directly (Riedel et al., 2006). Some of
the instrumentation used (Table 2) differed to that reported in
the original methods. Carboxyhemoglobin (COHb) was measured
in blood by spectrophotometry (Pojer et al., 1984).
Biomarker analyses were performed at Synevo Clinical Trials,
Central Laboratory Services, Gdan´sk, Poland (Synevo), Philip Morris
Research Laboratories GmbH, Cologne Germany (PMRL), MTZ, and
MDS Pharma Services, Fehraltorf, Switzerland (MDS).2.5. Medications
All previous and ongoing concomitant medications were re-
corded prior to and during the course of the study. Use of any med-
ication that might have interfered with study results was not
allowed; this included anti-inﬂammatory drugs, hormonal thera-
pies, or nicotine replacement therapy. Paracetamol (acetamino-
phen) was allowed up to 1500 mg/day.2.6. Safety evaluations
Safety evaluations were conducted on a weekly basis from
Visits 2 to 8 and included adverse events (AEs), concomitant
medications, and vital signs. ECG and physical examinations were
conducted at Visits 1 and 8. A complete safety laboratory assess-ethod Lower limit of quantiﬁcation
low cytometry 0.1  109/L
low cytometry 0.1  109/L
C detection method 10  109/L
C detection method 0.02  1012/L
pectrophotometry 0.1 g/dL
umulative pulse height detection method 0.1%
mmuno-turbidimetry 0.03 mg/L
LISA 2 pg/mL
LISA 4.13 ng/mL
LISA 1.6 ng/mL
icroparticle enzyme immunoassay 0.8 lmol/L
hotometry 3 mg/dL
hotometry Derived
hotometry 3 mg/dL
LISA 0.14 U/mL
lot detection 1.5 g/L
DP-induced blood platelet aggregation 1%
C–MS/MS 0.282 nmol/L
C–MS/MS 0.678 nmol/L
tography–mass spectrometry/mass spectrometry.
Table 2
Summary of smoke constituent biomarkers of exposure and bioanalytical methods.
Smoke constituent Biomarker Matrix Analytical methoda Lower limit of quantiﬁcation
1,3-Butadiene Monohydroxybutenyl mercapturic acid (MHBMA) Urine LC–MS/MS 100 pg/ml
2-Naphthylamine 2-Naphthylamine (2-NA) Urine LC–MS/MS 5.0 pg/ml
4-Aminobiphenyl 4-Aminobiphenyl (4-ABP) Urine LC–MS/MS 5.0 pg/ml
Acrolein 3-Hydroxypropyl mercapturic acid (3-HPMA) Urine LC–MS/MS 35 ng/ml
Benzene S-Phenyl mercapturic acid (S-PMA) Urine LC–MS/MS 20 pg/ml
Carbon monoxide Carboxyhemoglobin (COHb) Blood Spectrophotometry 0.3% Saturation
Nicotine Nicotine equivalents (NEq)c Urine LC–MS/MS NAf
NNKb Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (total NNAL)d Urine LC–MS/MS 5.0 pg/ml
Pyrene Total 1-hydroxypyrene (total 1-OHP)e Urine LC–MS/MS 10 pg/ml
o-Toluidine o-Toluidine (o-TOL) Urine LC–MS/MS 25 pg/ml
a LC–MS/MS, liquid chromatography–tandem mass spectrometry.
b NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
c Nicotine equivalents (NEq) were determined as the molar sum of nicotine, cotinine, and trans-30-hydroxycotinine plus their respective glucuronide conjugates.
d Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) was determined as the molar sum of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its O-glucuronide
conjugate.
e Total 1-hydroxypyrene (1-OHP) was determined as the molar sum of 1-hydroxypyrene and its glucuronide and sulfate conjugates.
f NA, not applicable.
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performed at Visits 1 and 8.
2.7. Data analysis
For the purpose of data analysis, the baseline value of biomark-
ers analyzed in blood was the mean of the values from Visits 2 and
3, and the end-of-study value (EOS) value was the mean of the val-
ues from Visits 7 and 8. For all urinary biomarkers, baseline and
end-of-study values were as measured at Visits 3 and 8,
respectively.
Two analysis sets were deﬁned. The full-analysis set (FAS) pop-
ulation consisted of all subjects who smoked at least one cigarette
following randomization, and had valid measurements of the pri-
mary biomarkers taken at baseline and at least once post-baseline.
The per-protocol (PP) population included subjects who completed
the study per protocol with good compliance, with baseline and
end-of-study measurements of the primary biomarkers, and with-
out major protocol deviations.
Descriptive statistics were provided for all biomarkers. Results
were stratiﬁed by study group. Biomarkers were analyzed using
the one-sample t-test for within-group changes and analysis of
covariance (ANCOVA) for between-group differences on reported,
untransformed values, if those values were normally distributed.
In case of signiﬁcant deviation from normality of the untrans-
formed data, but not for log-transformed data, both data types
were analyzed using the above tests. If non-normality was de-
tected for both data types, statistical analysis was performed using
non-parametric methods. The within-study group change from
baseline to the end-of-study was analyzed using Wilcoxon rank
sum test. The same test was used for the comparison of the two
study groups with regard to absolute end-of-study values and
changes from baseline to end-of-study.
Analyses for the two primary biomarkers, hs-CRP and WBC,
were performed on per-protocol and full-analysis-set populations.
Analyses for other biomarkers were performed for the full-analy-
sis-set population only.
Since this was an exploratory study, no adjustment for multi-
plicity was made. All results from inferential statistics should be
considered as indicative only. All statistical analyses were per-
formed using SAS V8.2 (SAS Institute Inc., Cary, NC, USA) accord-
ing to a predeﬁned statistical analysis plan.
2.8. Determination of sample size
Sample-size estimation was based on the observed variability
in a previous study (Roethig et al., 2008) for the two primarybiomarkers, hs-CRP and WBC. The estimated sample size for this
study was 80 subjects per study group to allow detection of effect
size of D = 0.47 for hs-CRP with a power of 80% at a signiﬁcance le-
vel a = 0.05 using a two-sided, two-sample t-test. The anticipated
effect size for WBC count (D = 0.66) was greater than that of hs-
CRP, so the calculated sample size for hs-CRP was considered to
be large enough for WBC count. The sample size was increased in
the EHCSS-K6 study group from 80 to 240 subjects to account for
possible non-compliance.
2.9. Adverse events, medical history, and concomitant medication
Adverse events (AEs) and medical history were coded using the
Medical Dictionary for Regulatory Activities (MedDRA Version 7.0).
Medications were coded according to the WHO Drug Reference List
(WHODrugDictionary, UppsalaMonitoring Center, 2003 quarter 4).
3. Results
3.1. Demographics and other baseline characteristics
A total of 338 subjects were enrolled in the study and 316 were
randomized (Fig. 2). Of the 316 randomized subjects, 237 were ran-
domized to the EHCSS-K6 and 79 to the CC group study group. For
the 22 subjects not randomized, the most common reasons were
AEs prior to randomization or violation of selection criteria. The
study was completed by 309 subjects, with 234 and 75 subjects
for the EHCSS-K6 and CC groups, respectively. Therewere 7 subjects
who did not complete the study. In the EHCSS-K6 group, 2 subjects
were withdrawn as they did not attend study visits and 1 subject
withdrew consent. In the CC group, 2 subjects were withdrawn as
they did not attend study visits, 1 subject was withdrawn due to
inﬂuenza and 1 subject for violation of selection criteria.
Of the 316 subjects, 161 (51%) were male and 155 (49%) were
female. The mean age of all subjects was 44 years old, with 52%
of subjects in the 30- to 44-year age group and 48% in the 45- to
60-year age group. The body mass index (BMI) classiﬁcation
showed 47.2% of subjects to have normal weight, 36.7% to be over-
weight, 13.6% to be obese, and 2.5% to be underweight (Table 3).
The Fagerström Test for Nicotine Dependence (FTND) scores
were similar for subjects subsequently randomized to both study
groups, with a mean of 5.9 ± 2.0 in both study groups. Smoking his-
tory was similar for both groups. The majority of subjects reported
a smoking history of greater than 20 years, 61% and 68% for the
EHCSS-K6 and CC groups, respectively.
Three major protocol deviations were observed in the study, all
in the EHCSS-K6 group. Two subjects did not fast prior to blood
Fig. 2. Subject disposition. A total of 338 subjects were enrolled on the study, of which 316 were randomized, and the study was completed by 309 subjects (234 and 75
subjects in the EHCSS-K6 and CC groups, respectively). EHCSS-K6, EHCSS series-K heater and cigarette (5 mg tar, 0.3 mg nicotine, and 1.0 mg CO); CC, conventional cigarette.
Table 3
Subject demographics by study group as measured at baseline.
Variable and statistics Study groupa
EHCSS-K6 CC Overall
Number of subjects (N) 237 79 316
Age (years, mean ± SD) 43.5 ± 8.0 43.9 ± 8.2 43.6 ± 8.1
Gender (N, % of total)
Male 121 (51) 40 (51) 161 (51)
Female 116 (49) 39 (49) 155 (49)
BMI (kg/m2 mean ± SD)b 25.15 ± 4.58 23.93 ± 3.29 24.84 ± 4.32
Classiﬁcation
Underweight (N, %) 6 (2.5) 2 (2.5) 8 (2.5)
Normal weight (N, %) 106 (44.7) 43 (54.4) 149 (47.2)
Overweight (N, %) 87 (36.7) 29 (36.7) 116 (36.7)
Obese (N, %) 38 (16.0) 5 (6.3) 43 (13.6)
a Groups abbreviated as: EHCSS-K6, EHCSS series-K heater and cigarette
(5 mg tar, 0.3 mg nicotine, and 1.0 mg CO); CC, conventional cigarette.
b BMI, body mass index.
Table 4
Daily cigarette consumption by group and study week.
Study week Study groupa
EHCSS-K6 CC
N Mean ± SD N Mean ± SD
1b 237 25 ± 6 79 25 ± 6
1 236 33 ± 5 77 24 ± 1
2 236 37 ± 1 75 24 ± 1
3 236 36 ± 5 75 23 ± 2
4 235 36 ± 4 75 23 ± 1
5 235 40 ± 2 75 23 ± 1
Allc 236 38 ± 3 77 23 ± 1
a Groups abbreviated as: EHCSS-K6, EHCSS series-K heater and cigarette
(5 mg tar, 0.3 mg nicotine, and 1.0 mg CO); CC, conventional cigarette.
b All subjects smoked CC during Week -1.
c Average daily cigarette consumption on Weeks 1–5.
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drugs within 2 weeks prior to screening. Minor deviations, related
to study timing or procedure, occurred in both study groups with
comparable frequencies and types of deviations reported.3.2. Cigarette consumption and compliance
The mean number of cigarettes smoked daily for both groups
were similar at baseline: 25 cigarettes per day (CPD) (Table 4). In
the EHCSS-K6 group, the average daily consumption increased over
the course of the study from 33 CPD in Week 1 to 40 CPD in Week
5, with an overall mean of 38 CPD across Visits 3–8. This increasing
trend for the EHCSS-K6 study group was consistent throughout the
subgroups for age and gender. For the CC group, the overall mean
across Visits 3–8 was 23 CPD.
For the full-analysis-set population, the mean compliance for
the EHCSS-K6 group, based on self-reporting in the e-diary, ranged
from 99% to 100%. A total of 13 subjects in this group reported
smoking CC on at least one occasion. Compliance rates for subjectsin the CC study group who continued to smoke their own type of
CC, based on self-reported data, ranged from 97.3% to 98.7%. Three
subjects in the CC group reported the use of other tobacco- or nic-
otine-containing products.3.3. Primary biomarkers
Baseline values were similar for the primary biomarkers hs-CRP
and WBC count. For the primary analysis of between-group com-
parisons at the end-of-study, no statistically signiﬁcant differences
were observed.
Within-group comparisons showed reductions in median ser-
um hs-CRP from baseline values (1.37 mg/L) to the end of study
(1.11 mg/L) for the EHCSS-K6 study group and from 1.18 to
0.85 mg/L in the CC group. However, the results using mean values
were different (Table 5), and it is therefore unclear whether there
was any real change.
There were no statistically signiﬁcant differences for WBC
counts between study groups at the end-of-study. A reduction in
mean WBC counts from baseline (7.09 ± 1.73  109/L) to the end-
of-study (6.90 ± 1.64  109/L) occurred in the EHCSS-K6 group.
Table 5
Summary of overall high sensitivity C-reactive protein (hs-CRP) concentrations at
baseline and end of study, and change from baseline to end of study by study group
(PP population).
Time point hs-CRP mg/L Study groupa
EHCSS-K6 CC
Baselineb Mean ± SD 2.20 ± 2.71 2.02 ± 2.49
Median (min., max.) 1.4 (0.2, 23.2) 1.2 (0.3, 11.7)
End of studyc Mean ± SD 2.04 ± 2.80 2.27 ± 5.34
Median (min., max.) 1.1 (0.2, 27.5) 0.8 (0.2, 35.5)
Change from
baseline
Mean ± SD 0.15 ± 3.41 0.25 ± 5.15
Median (min., max.) 0.1 (21.4, 26.0)d 0.1 (11.2, 30.1)
a Groups abbreviated as: EHCSS-K6, EHCSS series-K heater and cigarette
(5 mg tar, 0.3 mg nicotine, and 1.0 mg CO); CC, conventional cigarette.
b Baseline values are a mean of Visits 2 and 3.
c End-of-study values are a mean of Visits 7 and 8.
d Statistically different from baseline (p 6 0.01).
Table 6
Summary of overall white blood cell (WBC) counts at baseline and end of study, and
change from baseline to end of study by study group (PP population).
Time point WBC count
(109/L)
Study groupa
EHCSS-K6 CC
Baselineb Mean ± SD 7.09 ± 1.73 7.00 ± 1.63
Median (min., max.) 6.9 (3.4, 12.7) 6.8 (4.2, 10.9)
End of studyc Mean ± SD 6.90 ± 1.64d 6.94 ± 1.60
Median (min., max.) 6.6 (3.7, 14.0) 6.9 (4.4, 11.0)
Change from
baseline
Mean ± SD 0.20 ± 1.23 0.06 ± 0.94
Median (min., max.) 0.2 (5.5, 5.3) 0.1 (2.7, 3.7)
a Groups abbreviated as: EHCSS-K6, EHCSS series-K heater and cigarette
(5 mg tar, 0.3 mg nicotine, and 1.0 mg CO); CC, conventional cigarette.
b Baseline values are a mean of Visits 2 and 3.
c End-of-study values are a mean of Visits 7 and 8.
d Statistically different from baseline (p 6 0.01).
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with mean WBC baseline levels of 7.00 ± 1.63  109/L, and end-
of-study levels of 6.94 ± 1.60  109/L (Table 6).
3.4. Other biomarkers associated with cardiovascular disease
Other biomarkers associated with CVD were found to be com-
parable at baseline. A summary of ﬁndings for these biomarkers
is presented in (Table 7).
A statistically signiﬁcant reduction (p < 0.05) in neutrophil
counts from 4.11 ± 1.35  109/L to 3.92 ± 1.28  109/L from base-
line to the end-of-study within the EHCSS-K6 group was observed.
An increase in high-density lipoprotein (HDL) cholesterol from
59.0 ± 16.3 mg/dL to 63.9 ± 17.3 mg/dL from baseline to the end-
of-study in the EHCSS-K6 group was found, but not in the CC group.
HDL was also higher in the EHCSS-K6 group (63.9 ± 17.3 mg/dL)
compared to the CC group at the end-of-study (62.3 ± 16.1 mg/
dL). Within-group analysis for baseline to end-of-study values re-
vealed statistically signiﬁcant decreases in the EHCSS-K6 group
of red blood cells (RBC, by 0.08  1012/L; p 6 0.001), hemoglobin
(by 0.29 g/dL; p 6 0.001), and hematocrit (by 0.92%; p 6 0.001).
End-of-study values of all three parameters in the EHCSS-K6
groups were lower than in the CC group. Statistical comparisons
between study arms (EHCSS-K6 vs. CC) at the end of the study
showed statistically signiﬁcant decreases in the EHCSS-K6 com-
pared to the CC study arms for RBC (p 6 0.01), hematocrit
(p 6 0.001), and hemoglobin (p 6 0.001).
A median decrease of 6 ng/mL was observed in myeloperoxi-
dase levels in the EHCSS-K6 group at the end-of-study, comparedto an increase of 23 ng/mL in the CC group. Neither of these
changes was statistically signiﬁcant. Urinary 11-DTXB2 excretion
decreased from baseline to the end-of-study in the EHCSS-K6
group from 14.47 ± 8.49 pg/24 h to 13.25 ± 8.68 pg/24 h. Although
there was a similar tendency in the CC group, this was of a smaller
magnitude. All other changes in biomarkers in this study were
either non-speciﬁc to the EHCSS-K6 group or were not considered
to be clinically relevant.
3.5. Biomarkers of exposure
Study groups were comparable with regards to levels of bio-
markers of exposure at baseline. All biomarkers of exposure mea-
sured in this study were signiﬁcantly reduced from baseline to
end-of-study in the EHCSS-K6 study group. Furthermore, at the
end-of-study all biomarkers of exposure were substantially lower
in the EHCSS-K6 group than in the CC group. A summary of the bio-
marker of exposure data is presented in Table 8.
In the EHCSS-K6 group a reduction in the percent saturation of
COHb from 4.35% ± 1.59% to 2.32% ± 1.07%, a reduction in total
NNAL from 346.1 ± 226.6 to 186.3 ± 147.1 ng/24 h, and a reduction
in S-PMA from 5.61 ± 7.64 to 2.00 ± 2.53 lg/24 h were observed.
Total nicotine equivalent (Neq) levels decreased from 17.93 ±
8.30 to 14.66 ± 7.90 mg/24 h from baseline to end-of-study in the
EHCSS-K6 group. A smaller decrease by 1.75 mg/24 h of Neq levels
was observed in the CC group, while changes in all other biomark-
ers of exposure were not signiﬁcant.
3.6. Safety evaluations/serious adverse events
Similar percentages of subjects reported AEs: 53% and 58% in
the EHCSS-K6 and CC groups, respectively. The most commonly re-
ported AEs that were considered related to the EHCSS-K6 cigarette
were dry mouth, dry throat, cough and diarrhea, which occurred in
0.4–1.3% of subjects.
Three serious adverse events (SAEs) were reported. A deep vein
thrombosis in the EHCSS-K6 group which occurred approximately
1 week after the end of the study when the subject had restarted
smoking CC. This event was considered by the investigator to be
possibly related to the EHCSS-K6 cigarette, as cigarette smoking
is a known risk factor for this condition. A post-traumatic splenic
injury (EHCSS-K6 study group) that occurred after the end of the
study, and was not considered to be related to the study product.
A myocardial infarction that occurred prior to randomization.
There were no apparent differences between groups in any of the
clinical laboratory values, vital signs, ECG parameters, or physical
examinations during the study.4. Discussion
This study was designed to compare biomarkers associated
with CVD and biomarkers of exposure to selected cigarette smoke
HPHC in subjects switching to the EHCSS-K6 cigarette compared to
those continuing to smoke conventional cigarettes in real-life, ac-
tual use conditions. In a similar randomized clinical trial conducted
over 12 months with an earlier prototype of the EHCSS and group
of smokers who used a 6 mg tar conventional cigarette (Roethig
et al., 2008), mean cigarette consumption increased from 24.3
and 23.3 CPD at baseline to 45.1 and 31.0 after Week 4, respec-
tively. Very similar to that reported in the current study in which
smokers of the EHCSS-K increased mean consumption from 25
CPD at baseline while smoking own-brand cigarettes to 38 CPD
when smoking EHCSS-K6 (Table 4), while no signiﬁcant change
in cigarette consumption occurred in smokers who continued to
smoker their own brand of CC (25 CPD). Providing EHCSS cigarettes
Table 7
Summary of biomarkers associated with cardiovascular disease.
Study groupa
EHCSS-K6 CC
Biomarkers associated
with cardiovascular disease
Baselineb (N = 236) EOSc (N = 235) Changed Baselineb (N = 77) EOSc (N = 75) Changed
Neutrophils (109/L)
Mean ± SD 4.11 ± 1.35 3.92 ± 1.28 0.187 ± 1.105 3.92 ± 1.37 3.91 ± 1.35 0.056 ± 0.772
Median (min., max.) 3.9 (1.5, 9.1) 3.7 (1.6, 10.7) 0.2 (5.3, 5.6) 3.7 (1.6, 7.8) 3.8 (1.5, 7.7) 0.2 (1.4, 2.6)
Lymphocytes (109/L)
Mean ± SD 2.13 ± 0.57 2.13 ± 0.55 0.003 ± 0.331 2.10 ± 0.52 2.12 ± 0.43 0.004 ± 0.308
Median (min., max.) 2.1 (1.0, 4.3) 2.0 (1.0, 3.8) 0.0 (1.1, 1.2) 2.0 (1.0, 4.5) 2.1 (1.2, 3.9) (0.0, 0.8, 0.6)
Monocytes (109/L)
Mean ± SD 0.646 ± 0.179 0.646 ± 0.177 0.000 ± 0.107 0.653 ± 0.160 0.661 ± 0.175 0.005 ± 0.114
Median (min., max.) 0.63 (0.28, 1.46) 0.63 (0.31, 1.36) 0.01 (0.30, 0.44) 0.62 (0.39, 1.19) 0.65 (0.35, 1.27) 0.01 (0.32, 0.36)
Eosinophils (109/L)
Mean ± SD 0.181 ± 0.099 0.184 ± 0.104 0.004 ± 0.067 0.212 ± 0.118 0.225 ± 0.121 0.010 ± 0.057
Median (min., max.) 0.17 (0.0, 0.54) 0.17 (0.0, 0.63) 0.00 (0.26, 0.26) 0.19 (0.04, 0.84) 0.20 (0.04, 0.84) 0.01 (0.15, 0.19)
Basophils (109/L)
Mean ± SD 0.026 ± 0.012 0.027 ± 0.014 0.001 ± 0.009 0.026 ± 0.011 0.028 ± 0.013 0.002 ± 0.008
Median (min., max.) 0.03 (0.01, 0.07) 0.03 (0.01, 0.08) 0.00 (0.03, 0.06)d 0.03 (0.01, 0.06) 0.03 (0.01, 0.07) 0.00 (0.02, 0.02)
HDL (mg/dL)
Mean ± SD 59.0 ± 16.3 63.9 ± 17.3 5.0 ± 8.5f 61.5 ± 16.3 62.3 ± 16.1 0.9 ± 7.1
Median (min., max.) 57 (27, 136) 63 (28, 123) 5 (54, 39) 54 (34, 116) 60 (35, 113) 1 (26, 20)
LDL (mg/dL)
Mean ± SD 121.5 ± 32.9 118.6 ± 31.2 3.4 ± 18.6g 120.8 ± 28.8 118.3 ± 30.1 3.0 ± 14.0
Median (min., max.) 122 (38, 212) 116 (33, 219) 4 (59, 49) 119 (56, 185) 119 (57, 194) 5 (41, 32)
Total cholesterol (mg/dL)
Mean ± SD 204.5 ± 35.3 207.0 ± 33.2 2.3 ± 21.1 203.6 ± 32.4 203.1 ± 31.2 1.2 ± 17.0
Median (min., max.) 203 (113, 333) 206 (116, 301) 3 (88, 66) 201 (144, 274) 198 (57, 194) 1 (46, 35)
RBC count (1012/L)
Mean ± SD 4.56 ± 0.41 4.48 ± 0.41 0.083 ± 0.175e 4.55 ± 0.39 4.54 ± 0.39 0.016 ± 0.143
Median (min., max.) 4.5 (3.7, 5.7) 4.4 (3.6, 5.5) 0.1 (1.2, 0.3) 4.5 (3.8, 5.4) 4.6 (3.6, 5.5) (0.4, 0.3)
Hemoglobin (g/dL)
Mean ± SD 14.29 ± 1.16 14.00 ± 1.18 0.29 ± 0.51e 14.28 ± 1.28 14.21 ± 1.32 0.06 ± 0.42
Median (min., max.) 14.3 (10.7, 17.3) 14.0 (10.3, 16.7) 0.3 (3.3, 0.8) 14.4 (10.5, 16.5) 14.3 (10.0, 16.5) 0.0 (1.1, 0.9)
Hematocrit (%)
Mean ± SD 42.67 ± 3.16 41.75 ± 3.08 0.92 ± 1.46e 42.58 ± 3.41 42.44 ± 3.50 0.10 ± 1.26
Median (min., max.) 42.6 (35.6, 50.4) 41.4 (34.6, 48.7) 0.8 (9.0, 2.2) 42.9 (34.0, 48.7) 43.1 (33.0, 48.6) 0.0 (3.5, 2.3)
IL6 (pg/mL)
Mean ± SD 1.39 ± 0.83 1.65 ± 3.00 0.25 ± 2.96 1.45 ± 1.04 1.41 ± 1.04 0.03 ± 1.26
Median (min., max.) 1.0 (1.0, 5.2) 1.0 (1.0, 39.5) 0.0 (3.9, 37.3) 1.0 (1.0, 6.4) 1.0 (1.0. 7.2) 0.0 (4.4, 6.2)
Ox LDL (ng/mL)
Mean ± SD 179.0 ± 485.7 184.2 ± 454.3 4.81 ± 188.5 167.3 ± 396.0 177.4 ± 365.9 6.21 ± 328.2
Median (min., max.) 36.7 (2.1, 3410) 59.0 (2.1, 4535) 15.5 (1472, 1280)f 47.2 (2.1, 2930) 58.6 (2.1, 2260) 8.8 (2158, 1028)g
Myeloperoxidase (ng/dL)
Mean ± SD 252.4 ± 107.6 245.5 ± 114.1 6.5 ± 86.0 239.1 ± 102.6 255.7 ± 113.4 17.1 ± 87.4
Median (min., max.) 223.5 (8.1, 676) 219.0 (3.0, 807) 6.3 (271.5, 278) 224.5 (90.8, 635) 231.0 (67.6, 575) 23.0 (220, 325)
8-epi-PGF2a (pg/24 h)
Mean ± SD 8.98 ± 4.14 9.08 ± 4.88 0.06 ± 4.57 8.63 ± 3.27 8.40 ± 4.30 0.32 ± 3.73
Median (min., max.) 8.4 (1.1, 26.2) 7.8 (1.1, 29.8) 0.17 (19.5, 21.1) 8.2 (1.4, 18.4) 7.6 (1.9, 22.1) 0.24 (8.3, 12.1)
Platelet count (109/L)
Mean ± SD 227.6 ± 51.4 230.5 ± 50.7 2.6 ± 23.3 221.7 ± 46.6 225.2 ± 51.0 2.8 ± 20.9
Median (min., max.) 222 (122, 393) 224 (118, 417) 1 (74, 108) 217 (133, 347) 223 (118, 338) 1 (43, 58)
Homocysteine (mol/L)
Mean ± SD 11.60 ± 3.22 11.76 ± 3.48 0.15 ± 1.56 12.21 ± 3.77 12.44 ± 3.86 0.22 ± 2.20
Median (min., max.) 10.9 (7.0, 30.8) 11.2 (6.8, 34.7) 0.2 (3.8, 10.7) 11.3 (7.1, 31.5) 11.7 (8.0, 30.4) 0.3 (6.3, 12.3)
vWF (U/l)
Mean ± SD 0.96 ± 0.31 0.81 ± 0.22 0.150 ± 0.217f 0.95 ± 0.29 0.77 ± 0.22 0.171 ± 0.207
Median (min., max.) 0.9 (0.4, 2.5) 0.8 (0.3, 1.7) 0.1 (1.7, 0.5) 0.9 (0.3, 1.8) 0.8 (0.3, 1.4) 0.1 (1.7, 0.5)
Fibrinogen (g/L)
Mean ± SD 3.6 ±(0.63 3.56 ± 0.62 0.040 ± 0.465 3.54 ± 0.72 3.60 ± 0.91 0.060 ± 0.537
Median (min., max.) 3.3 (2.2, 5.3) 3.5 (2.3, 5.8) 0.1 (1.3, 2.6) 3.5 (2.2, 6.0) 3.5 (2.1, 7.0) 0.0 (1.3, 2.7)
11-DTXB2 (pg/24 h)
Mean ± SD 14.47 ± 8.49 13.25 ± 8.68 1.18 ± 6.97 13.55 ± 5.62 13.33 ± 6.78 0.25 ± 5.11
Median (min., max.) 12.7 (1.7, 81.0) 11.4 (1.2, 81.0) 1.3 (23.8, 34.1)f 13.6 (1.7, 28.1) 12.4 (1.6, 42.6) 0.4 (13.2, 20.9)
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Table 7 (continued)
Study groupa
EHCSS-K6 CC
Biomarkers associated
with cardiovascular disease
Baselineb (N = 236) EOSc (N = 235) Changed Baselineb (N = 77) EOSc (N = 75) Changed
ADP-induced platelet
aggregation: slope
Mean ± SD 117.2 ± 19.9 120.2 ± 21.2 2.9 ± 19.5d 117.4 ± 22.5 120.5 ± 23.1 2.9 ± 16.2
Median (min., max.) 116 (68, 192) 117 (50, 189) 3 (142, 68) 115 (85, 187) 118 (85, 193) 3 (39, 45)
ADP-induced platelet
aggregation: amplitude
(%)
Mean ± SD 76.6 ± 5.0 78.4 ± 5.3 1.7 ± 5.5 77.2 ± 5.2 78.8 ± 4.3 1.6 ± 4.6
Median (min., max.) 78 (59, 86) 79 (39, 100) 2 (28, 25)f 78 (61,86) 79 (66, 86) 1 (10, 13)g
Abbreviations: ADP, adenosine diphosphate; CC, conventional cigarettes; 11-DTXB2, 11-dehydro-thromboxane B2; EHCSS-K6, electrically heated cigarette smoking system K6;
EOS, end of study; 8-epi-PGF2a, 8-epi-prostaglandin F2a; HDL, high-density lipoprotein; IL-6, interleukin-6; LDL, low-density lipoprotein; RBC, red blood cell count; oxLDL,
oxidized low-density lipoprotein; vWF, von Willebrand factor.
a Groups abbreviated as: EHCSS-K6, EHCSS series-K heater and cigarette (5 mg tar, 0.3 mg nicotine, and 1.0 mg CO); CC, conventional cigarette.
b Baseline measures are mean values of Visits 2 and 3 and all subjects smoked conventional cigarettes.
c End-of-study values are mean values of Visits 7 and 8.
d Change from baseline to end of study.
e Statistically different from baseline (p 6 0.05).
f Statistically different from baseline (p 6 0.001).
g Statistically different from baseline (p 6 0.01).
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sumption in the EHCSS group which could also be due to the re-
duced number of eight puffs the subjects could obtain using the
EHCSS (Werley et al., 2008; Schorp et al., 2012), while users of
CC average 12–13 puffs per cigarette (Perkins et al., 2012).
In the present study, no major changes were seen in the primary
biomarkers, hs-CRP, or WBC count. However, there were reduc-
tions, albeit not signiﬁcant, within the EHCSS-K6 group from base-
line to the end-of-study for both parameters.
The choice of both primary biomarkers was based on a previous
clinical study in which a non-signiﬁcant reduction in serum hs-CRP
and a signiﬁcant reduction in WBC count were observed over a 12-
month study period in subjects who switched from smoking CC to
an EHCSS (Roethig et al., 2008). The serum concentrations of hs-
CRP were noted to be highly variable, and therefore a larger sample
size than planned would have been needed in order to detect dif-
ferences in this biomarker. Post-hoc sample size calculations indi-
cated that, with the variability reported in this study, at least 312
subjects in each group would be necessary to detect the difference
in hs-CRP that was anticipated in the current study. There is evi-
dence to suggest that the observed variability may be a reﬂection
of the sensitivity of hs-CRP to even mild levels of inﬂammation (Ze-
dler et al., 2006). A study of smoking cessation evaluated markers
of inﬂammation indicated that inﬂammatory markers such as hs-
CRP resolve slowly over time even with complete cessation (Bakh-
ru and Erlinger, 2005). Given the long resolution time, contradic-
tory information regarding the effects of smoking on hs-CRP and
acute elevations not speciﬁc to current smoking behaviors, hs-
CRP would not be recommended as a primary endpoint in studies
assessing tobacco products over short study periods.
WBC count has also been implicated as a marker for early ath-
erosclerotic disease, and an independent marker of elevated risk
for CVD events (Calapai et al., 2009; Kannel et al., 1992; Lavi
et al., 2007). In highly controlled clinical studies in which smokers
switched from smoking CC to EHCSS, a signiﬁcant reduction in
WBC count was reported within 3 days suggesting a rapid reduc-
tion in inﬂammation (Roethig et al., 2010). However, under less
controlled conditions, statistically signiﬁcant reductions in WBC
count have been reported to occur much later: 4 weeks on smoking
cessation (Abel et al., 2005) and 7 weeks on smoking cessation
(Hatsukami et al., 2005). Although WBC count is clinically relevantand likely to be a suitable biomarker for measuring inﬂammation
in studies of tobacco products, the current study duration may
have been too short to evaluate changes in WBC count in subjects
switching to smoke EHCSS-K6 under non-controlled, actual use
ambulatory conditions.
Low HDL levels have been associated with smoking and also
with an increased risk of CVD (Benowitz, 2003). The reversibility
of HDL with smoking cessation is well documented, and recent evi-
dence now suggests that this biomarker may also be reversible
with reduction of smoking (Andrews and Tingen, 2006; Benowitz,
2003; Hatsukami et al., 2005). An increase in HDL levels has been
observed as early as 1 week following smoking cessation, and after
only 2 weeks in studies investigating reduction in cigarette con-
sumption (Benowitz, 2003; Eliasson et al., 2001; Hatsukami et al.,
2005; Minami et al., 2002). In a previous assessment of an EHCSS,
these increases were maximal at 3 months and were sustained
over the course of a 12-month study period (Roethig et al.,
2008). The HDL increase observed in this study was similar to that
reported in previous studies in both time and magnitude (Hatsuka-
mi et al., 2005). The rise of HDL levels of 5 mg/dL (approximately
8%) for the EHCSS-K6 group in the present study is within the re-
ported 5–15% range typically reported with the use of statins for
reducing CVD risk (Kapur et al., 2008). This increase may represent
a beneﬁcial shift, since there is evidence to support a 2% decrease
in CVD risk for every 1 mg/dL increase in HDL levels (Kapur
et al., 2008). These results support previous ﬁndings that switching
from CC to smoke an EHCSS may alter lipid proﬁles in a favorable
manner even when smokers increased the number of cigarettes
smoked (Roethig et al., 2008).
Higher levels of hematocrit and hemoglobin have been demon-
strated in smokers, and these increases are likely to be compensa-
tory for exposure to CO (Roethig et al., 2008). Increased binding of
CO to hemoglobin has been linked to the increased red cell mass,
hematocrit, and hemoglobin concentrations observed in smokers
that may contribute to a hypercoagulable state (Benowitz, 2003).
The present study supports previous EHCSS investigations in which
these parameters were reduced in combination with a signiﬁcant
reduction in CO exposure as measured by COHb (Roethig et al.,
2007, 2008). Previous investigations with EHCSS products have
found as much as 90% reductions in COHb levels, in as few as
8 days using the EHCSS cigarette (Roethig et al., 2005, 2007).
Table 8
Summary of biomarkers of exposure at baseline and end of study (FAS population).
Biomarker of exposure Study groupa
EHCSS-K6 CC
Baselineb (N = 236) EOSc (N = 235) Changed Baselineb (N = 77) EOSc (N = 75) Changed
COHb (%)
Mean ± SD 4.35 ± 1.59 2.32 ± 1.07 2.02 ± 1.41 4.70 ± 1.67 4.90 ± 1.57 0.22 ± 0.91
Median (min., max.) 4.2 (1.1, 9.8) 1.9 (1.1, 7.7) 2.0 (8.1, 1.7)e 4.7 (1.4, 8.2) 5.1 (1.3, 8.5) 0.1 (1.9, 3.4)
Neq/24 h (mg/24 h)
Mean ± SD 17.93 ± 8.30 14.66 ± 7.90 3.21 ± 6.55 19.75 ± 8.25 17.84 ± 7.98 1.75 ± 5.42
Median (min., max.) 17.3 (0.4, 49.3) 13.3 (0.4, 45.7) 3.3 (26.3, 22.9)e 19.0 (2.9, 41.7) 18.1 (3.1, 45.9) 0.9 (15.6, 14.5)f
3-HPMA (mg/24 h)
Mean ± SD 2.45 ± 1.66 1.93 ± 1.18 0.51 ± 1.59 2.31 ± 1.12 2.52 ± 1.41 0.22 ± 1.06
Median (min., max.) 2.2 (0.1, 14.0) 1.7 (0.1, 7.1) 0.3 (11.5,4.0)e 2.2 (0.4, 5.5) 2.2 (0.4, 8.1) 0.0 (3.7, 4.8)
S-PMA (lg/24 h)
Mean ± SD 5.61 ± 7.64 2.00 ± 2.53 3.60 ± 6.69 5.66 ± 3.67 5.38 ± 3.61 0.30 ± 2.57
Median (min., max.) 4.4 (0.2, 106.9) 1.2 (0.2, 23.4) 2.5 (89.8, 9.1)f 5.0 (0.54, 18.3) 5.0 (0.3, 19.3) 0.0 (10.2, 4.5)
MHBMA (lg/24 h)
Mean ± SD 8.53 ± 6.48 4.01 ± 4.05 4.51 ± 5.08 9.52 ± 6.34 8.18 ± 5.26 1.38 ± 3.96
Median (min., max.) 7.6 (0.1, 35.5) 2.7 (0.2, 25.8) 3.7 (29.0, 7.4)e 8.9 (0.4, 30.1) 7.7 (0.5, 25.3) 0.7 (14.4, 7.8)g
NNAL (ng/24 h)
Mean ± SD 346.1 ± 226.6 186.3 ± 147.1 160.3 ± 179.7 369.3 ± 213.3 358.3 ± 222.4 14.4 ± 134.9
Median (min., max.) 316.8 (9.5, 1653.3) 325.5 (49.1, 3803) 132 (1456, 301.5)e 378.6 (15.0, 1055.2) 318.6 (53.9, 1021.4) 11.6 (359.2, 338.8)
1-OHP (ng/24 h)
Mean ± SD 614.2 ± 766.0 450.2 ± 469.8 164.3 ± 747.5 514.6 ± 334.8 547.9 ± 364.6 29.5 ± 324.3
Median (min., max.) 492.8 (137.3, 10929) 148.8 (8.8, 939.3) 161 (8740, 3525)e 460.5 (123.9, 2216) 488.1 (104.5, 2085) 14 (1698, 1523)
4-ABP (ng/24 h)
Mean ± SD 27.12 ± 16.83 13.28 ± 19.23 13.80 ± 20.29 29.24 ± 15.81 28.71 ± 15.40 0.57 ± 11.15
Median (min., max.) 23.8 (1.3, 84.6) 8.8 (1.2, 243.0) 13.6 (77.4, 179.3)e 29.8 (3.2, 82.6) 25.8 (3.9, 71.7) 1.7 (18.9, 38.5)
o-Toluidine (ng/24 h)
Mean ± SD 302.0 ± (159.8) 184.0 ± (124.1) 116.7 ± (146.6) 313.0 ± (167) 334.4 ± (464.1) 22.9 ± (468.0)
Median (min., max.) 275.8 (34.5, 1222.7) 145.0 (34.9, 803.5) 114 (846.5, 445.1)e 294.8 (77.1, 1018.9) 255.1 (60.6, 4104.0) 20.5 (644.5, 3888.9)g
2-NA (ng/24 h)
Mean ± SD 35.23 ± 17.35 17.05 ± 14.30 18.28 ± 17.08 38.14 ± 37.65 37.65 ± 17.97 0.26 ± 11.7
Median (min., max.) 35.2 (2.5, 91.2) 12.1 (2.2, 81.5) 18.5 (74.5, 57.8)e 37.7 (1.3, 87.0) 36.7 (5.5, 80.6) 1.3 (24.2, 31.6)
Breath CO (ppm)h
Mean ± SD 11.4 ± 6.3 4.6 ± 4.3 6.7 ± 6.1 12.4 ± 6.7 13.6 ± 7.0 1.3 ± 6.2
Median (min., max.) 11 (0, 34) 4 (0, 20) 6 (31, 7) 11 (0, 30) 14 (0, 30) 0 (13, 21)
Abbreviations: 4-ABP, 4-aminobiphenyl; CO, carbon monoxide; COHb, carboxyhemoglobin; EOS, end of study; FAS, full-analysis set population; 3-HPMA, 3-hydroxypropyl
mercapturic acid; MHBMA, monohydroxybutenyl mercapturic acid; 2-NA, 2-aminonaphthalene; Neq/24 h, urinary nicotine equivalents quantity excreted in 24 h; NNAL, 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its glucuronides; 1-OHP, 1-hydroxypyrene and its glucuronide and sulfate conjugates; S-PMA, S-phenyl mercapturic acid.
a Groups abbreviated as: EHCSS-K6, EHCSS series-K heater and cigarette (5 mg tar, 0.3 mg nicotine, and 1.0 mg CO); CC, conventional cigarette.
b Baseline measures are mean values of Visits 2 and 3 and all subjects smoked conventional cigarettes.
c End-of-study values are mean values of Visits 7 and 8.
d Change from baseline to end of study.
e Statistically different from baseline (p 6 0.001).
f Statistically different from baseline (p 6 0.01).
g Statistically different from baseline (p 6 0.05).
h Normal range in smokers is 0-5 ppm. No statistical analyses were performed for breath CO.
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smokers compared to non-smokers, and may be a prognostic indi-
cator of CVD events (Calapai et al., 2009). It is a potent vasocon-
strictor and an in vivo marker of platelet aggregation and
activation, both of which may make it an indicator of atherosclero-
sis or a hypercoagulable state (Benowitz, 2003; Zedler et al., 2006).
The dose-dependent platelet inhibition and anticoagulation effects
of acetyl salicylic acid (ASA) in clinical settings, and the resultant
protection against secondary CVD events, are thought to be ex-
plained by the effect of ASA on mechanisms involving thrombox-
ane (EMEA, 2002). The changes observed regarding 11-DTXB2 in
the EHCSS-K6 group support the use of 11-DTXB2 in future studies
of tobacco products.
The reductions of biomarkers of exposure observed in this study
for the EHCSS-K6 group were generally of a large magnitude for a
broad spectrum of cigarette smoke HPHC and occurred despite the
observed increase of the daily consumption of cigarettes. However,
for many of the biomarkers the extent of the reductions were smal-
ler in this study than in a previous EHCSS-K6 study performed in aconﬁnement setting (with capped cigarette consumption) in the
United Kingdom (Tricker et al., 2012a). For example COHb, S-
PMA and nicotine equivalents were reduced by 70%, 80%, and
44% in the previous conﬁnement study compared to 50%, 48%
and 7%, respectively, in this study. This is noteworthy since a
reduction of CC consumption and/or CC tar yields in many studies
does not necessarily result in a reduction in biomarkers of expo-
sure to HPHC (Hatsukami et al., 2006a,b; Lubin et al., 2007; Joseph
et al., 2008).
While in short-term conﬁnement studies, it is possible to obtain
accurate data about the types and quantities of cigarettes smoked,
longer-term ambulatory studies are reliant on accurate self-report-
ing. It would be beneﬁcial to develop and validate a biomarker for
detection of dual use of a test cigarette (e.g., EHCSS-K6) and CC.
It should be noted that the EHCSS-K6 cigarettes were supplied
without charge in this study, whereas smokers of conventional cig-
arettes had to purchase their cigarettes. This is a potential source of
bias for smoking behavior that may have contributed in the in-
creased cigarette consumption in the EHCSS-K6 group.
C. Martin Leroy et al. / Regulatory Toxicology and Pharmacology 64 (2012) S74–S84 S835. Conclusions
In conclusion, the data from the current study indicate potential
favorable changes in some biomarkers associated with CVD in
smokers who have switched to the EHCSS-K6 cigarette over a 1-
month period. Switching from conventional cigarettes to the
EHCSS-K6 results in reductions in all biomarkers of exposure mea-
sured even with an increasing number of EHCSS-K6 cigarettes
smoked, supporting previous ﬁndings. However, none of the reduc-
tions in biomarkers of exposure between the EHCSS-K6 and con-
ventional cigarettes groups was signiﬁcant. Future studies should
investigate both larger sample sizes and longer durations of exclu-
sive exposure to evaluate the effect on CVD biomarkers.Conﬂict of interest statement
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